Lataa...
Targeted therapies for ER+/HER2- metastatic breast cancer
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine res...
Tallennettuna:
| Julkaisussa: | BMC Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462184/ https://ncbi.nlm.nih.gov/pubmed/26059247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0369-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|